Symptom Burden In Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

被引：0
|
作者：
Williams, Loretta A.
Ault, Patricia S.
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
Quintas-Cardama, Alfonso
Borthakur, Gautam
Faderl, Stefan H.
Jabbour, Elias J.
Cleeland, Charles S.
Cortes, Jorge E.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2988
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Are Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Occurring during the Course of Lymphoma (Ly) Always Therapy Related?
    Bigenwald, Camille
    Harel, Stephanie
    Chevillon, Florian
    Roos-Weil, Damien
    Bernard, Olivier A.
    Amorim, Sandy
    Brice, Pauline
    Lionel, Ades
    Nloga, Anne Marie
    Sebert, Marie
    Braun, Thorsten
    Eclache, Virginie
    Thieblemont, Catherine
    Fenaux, Pierre
    BLOOD, 2015, 126 (23)
  • [42] Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
    Cashen, Amanda F.
    Shah, Ajit K.
    Todt, Laura
    Fisher, Nicholas
    DiPersio, John
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (05) : 759 - 766
  • [43] Immediate Allogeneic Hematopoietic Cell Transplantation (HCT) in Acute Myeloid Leukemia (AML) Arising From Myelodysplastic Syndrome (MDS)
    Kim, Sung-Doo
    Choi, Yunsuk
    Park, Young-Hun
    Lee, Jae Seok
    Kim, Dae-Young
    Lee, Jung-Hee
    Lee, Kyoo-Hyung
    Seol, Miee
    Lee, Young-Shin
    Kang, Young-Ah
    Jeon, Mijin
    Jung, Ah Rang
    Lee, Je-Hwan
    BLOOD, 2011, 118 (21) : 888 - 889
  • [44] Population pharmacokinetic modelling of decitabine in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
    Mistry, B.
    Gibiansky, L.
    Hussein, Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [45] MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID LEUKEMIAS (AML) WITH MYELOFIBROSIS
    IMBERT, M
    NGUYEN, D
    SULTAN, C
    LEUKEMIA RESEARCH, 1992, 16 (01) : 51 - 54
  • [46] Generation of leukemia-derived dendritic cells (DCleu) as a basis for specific immunotherapy in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
    Schmetzer, H
    Schmid, C
    Kufner, S
    Pelka-Fleischer, R
    Kroell, T
    Zitzelsberger, H
    de Valle, P
    Treder, W
    Salih, H
    Kolb, HJ
    BLOOD, 2004, 104 (11) : 698A - 698A
  • [47] CYTOGENETIC EVOLUTION FOLLOWING TRANSFORMATION OF MYELODYSPLASTIC SYNDROME (MDS) TO ACUTE MYELOGENOUS LEUKEMIA (AML)
    GHADDAR, H
    STASS, S
    CORK, A
    ESTEY, E
    BLOOD, 1993, 82 (10) : A376 - A376
  • [48] Acute myelogenous leukemia (AML) type induction chemotherapy for the patients with myelodysplastic syndrome (MDS)
    Kim, D.-Y.
    Kim, J.-S.
    Kim, B.-S.
    Bang, S.-M.
    Kim, I.
    Yoon, S.-S.
    Park, S.
    Kim, B. K.
    LEUKEMIA RESEARCH, 2007, 31 : S138 - S138
  • [49] Treatment Results of Intensive Chemotherapy for Higher-Risk Myelodysplastic Syndrome (HR-MDS) and Acute Myeloid Leukemia Related to MDS (MDS-AML)
    Kyo, Taiichi
    Yoshida, Noriaki
    Kyo, Kouhei
    Okatani, Takeshi
    Itagaki, Mitsuhiro
    Yuasa, Hiromi
    Iwato, Koji
    Asaoku, Hideki
    Katayama, Yuuta
    BLOOD, 2010, 116 (21) : 1209 - 1210
  • [50] Clonality of peripheral blood cells in acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS)
    Keyhani, A
    Gengenbacher, D
    SanchezWilliams, G
    Goodacre, A
    Andreeff, M
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 1347 - 1347
12345